Pages that link to "Q45248007"

The following pages link to Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis (Q45248007):

Displaying 48 items.

• Sunitinib in the treatment of metastatic renal cell carcinoma (Q28072057) (← links)
• Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells (Q28078154) (← links)
• Sunitinib in solid tumors (Q28245467) (← links)
• Renal cell cancer: overview of the current therapeutic landscape. (Q30248354) (← links)
• Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry (Q33887804) (← links)
• The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. (Q33946316) (← links)
• Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma (Q34779020) (← links)
• Advances in renal cell carcinoma treatment (Q35076407) (← links)
• A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate (Q35316783) (← links)
• Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review (Q35583953) (← links)
• Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. (Q35657061) (← links)
• NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy (Q36318627) (← links)
• Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma (Q37283720) (← links)
• Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer (Q37404382) (← links)
• Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies (Q37438970) (← links)
• Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer (Q37614576) (← links)
• Update on systemic therapies of metastatic renal cell carcinoma (Q37697631) (← links)
• Patient-based strategy for systemic treatment of metastatic renal cell carcinoma (Q37732294) (← links)
• An update on targeted therapy in metastatic renal cell carcinoma (Q37748050) (← links)
• Treatment of metastatic renal cell carcinoma. (Q37748477) (← links)
• Present state of target therapy for disseminated renal cell carcinoma (Q37773245) (← links)
• Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. (Q37830778) (← links)
• Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action (Q37866796) (← links)
• Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement (Q37898560) (← links)
• Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. (Q37952233) (← links)
• Sorafenib for the treatment of renal cancer (Q37977494) (← links)
• Treatment selection in metastatic renal cell carcinoma: expert consensus (Q37999655) (← links)
• Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. (Q38016794) (← links)
• Second-line systemic therapy for the treatment of metastatic renal cell cancer. (Q38020244) (← links)
• Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. (Q38163976) (← links)
• The bevacizumab experience in advanced renal cell carcinoma (Q41899102) (← links)
• Systemic therapy of renal cell carcinoma (Q42791098) (← links)
• Targeted therapies for renal cell carcinoma: more gains from using them again. (Q43121227) (← links)
• Current state of systemic therapy of metastatic renal cell carcinoma (Q43294578) (← links)
• Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (Q43980382) (← links)
• Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. (Q46033944) (← links)
• Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma (Q48208532) (← links)
• Targeting tumour microenvironment by tyrosine kinase inhibitor. (Q49887906) (← links)
• Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike? (Q51047061) (← links)
• Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. (Q52896102) (← links)
• Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. (Q53086758) (← links)
• Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. (Q53417538) (← links)
• Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. (Q54599109) (← links)
• [Systemic and surgical management of metastatic renal cell carcinoma] (Q82083397) (← links)
• Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-l (Q83770417) (← links)
• Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy? (Q88030447) (← links)
• Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma (Q90733984) (← links)
• Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma (Q91994863) (← links)